By Fineline Cube Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with South Korea’s Samil Pharmaceuticals, Co., Ltd. (000520.KS), granting Samil exclusive commercialization rights in the Vietnamese market for clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative drug leveraging Formosa’s proprietary nanoparticle technology.
Deal Structure & Geographic Expansion
| Component | Detail |
|---|---|
| Parties | Formosa Pharmaceuticals (TPE: 6838) and Samil Pharmaceuticals (000520.KS) |
| Agreement Type | Exclusive licensing agreement |
| Territory | Vietnam |
| Product | APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) |
| Drug Classification | Patented innovative ophthalmic corticosteroid |
| Partnership Context | Follows previous agreement securing South Korean rights for APP13007 |
| Technology Platform | Formosa’s proprietary APNT nanoparticle formulation platform |
Product Profile & Clinical Advantages
- Active Ingredient: Clobetasol propionate – classified as a superpotent corticosteroid
- Innovation: Utilizes APNT nanoparticle formulation platform to enhance drug delivery and bioavailability
- Regulatory Status: Approved by US FDA in 2024 for post-ocular surgery inflammation and pain management
- Dosing Regimen: Convenient twice-daily administration for 14 days – significantly simpler than conventional corticosteroid regimens requiring 4-6 daily doses
- Clinical Benefits: Provides rapid onset and sustained relief of inflammation and pain following ocular surgery
Strategic Partnership Evolution
| Partnership Phase | Territory | Significance |
|---|---|---|
| Phase 1 (Previous) | South Korea | Established foundation for collaboration; leveraged Samil’s strong domestic pharmaceutical presence |
| Phase 2 (Current) | Vietnam | Expands geographic footprint into Southeast Asia’s rapidly growing pharmaceutical market |
| Future Potential | Additional ASEAN markets | Framework established for potential expansion across the region |
Samil Pharmaceuticals, one of South Korea’s leading pharmaceutical companies with established international operations, brings extensive commercial infrastructure and regulatory expertise to accelerate APP13007’s market penetration in Vietnam.
Market Opportunity & Competitive Landscape
- Vietnamese Ophthalmic Market: Valued at approximately $180 million in 2025, growing at 12% CAGR driven by aging population and increasing cataract surgery volumes
- Post-Surgical Care Gap: Limited access to advanced anti-inflammatory therapies in Vietnam’s public healthcare system creates significant unmet need
- Competitive Advantage: APP13007’s twice-daily dosing represents a major improvement over existing four-to-six times daily regimens, potentially improving patient compliance and clinical outcomes
- Pricing Power: FDA-approved innovative status supports premium pricing compared to generic alternatives currently available in the Vietnamese market
Forward‑Looking Statements
This brief contains forward-looking statements regarding the Formosa-Samil partnership, including market expansion plans, commercial expectations, and regulatory developments in Vietnam. Actual results may differ due to risks including local regulatory approvals, pricing negotiations, competitive dynamics, and market adoption rates.-Fineline Info & Tech